可溶性LOX-1预测急性冠脉综合征的过早死亡
在SPUM-ACS多中心前瞻性研究中,检测2924例ACS、CCS患者及健康对照的血浆sLOX-1,发现ACS患者sLOX-1显著升高,且独立关联30天和1年死亡风险;在系列冠脉影像和他汀治疗患者中,sLOX-1持续高与斑块进展相关。
要点
- ACS患者血浆sLOX-1水平显著高于CCS和健康对照
- sLOX-1独立预测ACS后30天和1年死亡风险,以心血管死亡为主
- sLOX-1持续高与冠脉斑块进展相关,下降见于斑块消退者
核心结论
- 血浆sLOX-1在ACS时升高,可预测传统和新兴风险因素之外的致命事件。
- 持续高sLOX-1与已确诊ASCVD患者的冠脉斑块进展相关。
研究设计与样本
- 多中心前瞻性SPUM-ACS研究,纳入ACS和CCS患者,并以性别年龄匹配的健康受试者为额外对照,共n=2924。
- 基线检测血浆sLOX-1,随访30天和1年死亡事件;部分ACS患者接受系列冠脉内成像和他汀治疗。
主要发现
- ACS患者sLOX-1中位数显著高于CCS和对照(35.08 vs 2.00和2.00 pg/mL,P<0.0001)。
- sLOX-1第三分位与30天死亡风险独立相关(调整HR 3.11,95%CI 1.44-10.61,P=0.0055)。
- sLOX-1第三分位与1年死亡风险独立相关(调整HR 2.04,95%CI 1.19-3.92,P=0.0098)。
- 调整GRACE 2.0后结果一致(T3:调整HR 1.86,95%CI 1.04-3.74,P=0.0391)。
- sLOX-1与30天心血管死亡(T3:调整HR 3.81,95%CI 1.62-19.62,P=0.0036)和1年心血管死亡(T3:调整HR 2.29,95%CI 1.19-5.34,P=0.0148)相关。
关键数值与推荐
- 斑块消退者1年时sLOX-1显著下降(ΔsLOX-1:-4.64 ± 1.80,P=0.0057)。
- sLOX-1预测斑块进展的AUC=0.74(95%CI 0.59-0.86,P=0.0031)。
临床怎么用
- ACS患者入院时可检测血浆sLOX-1,辅助识别30天和1年死亡高风险人群。
- 对已确诊ASCVD患者,动态监测sLOX-1可能有助于评估斑块进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and its shedding product [soluble LOX-1 (sLOX-1)] are implicated in atherosclerotic cardiovascular disease (ASCVD) pathogenesis. Herein, we examined the relationship of sLOX-1 with both fatal events and plaque progression in patients with acute coronary syndromes (ACS). METHODS AND RESULTS: Plasma sLOX-1 was assessed at baseline in ACS and chronic coronary syndrome (CCS) patients prospectively recruited in the multicentre SPUM-ACS study, with sex- and age-matched healthy subjects serving as additional controls (n = 2924). Compared with both CCS and controls, ACS patients showed markedly elevated sLOX-1 levels (median, 2.00 and 2.00 vs. 35.08 pg/mL; P < 0.0001) which were independently associated with increased mortality risk over 30-day [tertile (T)3: adjusted hazard ratio (HR), 3.11; 95% confidence interval (CI), 1.44-10.61; P = 0.0055] and 1-year intervals (T3: adjusted HR, 2.04; 95% CI, 1.19-3.92; P = 0.0098). Results remained consistent after adjustment for GRACE 2.0 (T3: adjusted HR, 1.86; 95% CI, 1.04-3.74; P = 0.0391) and were primarily driven by the pronounced relationship of sLOX-1 with cardiovascular mortality at 30 days (T3: adjusted HR, 3.81; 95% CI, 1.62-19.62; P = 0.0036) and at 1 year (T3: adjusted HR, 2.29; 95% CI, 1.19-5.34; P = 0.0148). In ACS patients undergoing serial intracoronary imaging and statin therapy, sLOX-1 dropped significantly in those with coronary plaque regression at 1 year (ΔsLOX-1: -4.64 ± 1.80; P = 0.0057), and showed a good discrimination for predicting plaque progression (area under the curve = 0.74; 95% CI, 0.59-0.86; P = 0.0031). CONCLUSION: Plasma sLOX-1 levels are increased during ACS and predict fatal events beyond traditional and emerging risk factors. Persistently high sLOX-1 associates with coronary plaque progression in patients with established ASCVD. CLINICAL TRIAL REGISTRATION: NCT01000701.
引用
- Kraler S, Wenzl FA, Georgiopoulos G, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. Eur Heart J. 2022. PMID: 35567560. doi:10.1093/eurheartj/ehac143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。